Related Experiment Video
Updated: Jan 1, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
The Role of Long Non-coding RNAs in Immunotherapy Resistance
Yuwen Zhou1, Yajuan Zhu1, Yao Xie2
1State Key Laboratory of Biotherapy, Department of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
T-cell-based immunotherapies, particularly immune checkpoint inhibitors, are promising treatments for various cancers. However, a large subset of patients develop primary or secondary resistance upon treatment. Although the detailed mechanisms remain unclear, immune escape via alterations in both cancer and tumor microenvironment has been identified as critical causes of immune resistance. Moreover, some long non-coding RNAs (lncRNAs), named as immune-related lncRNAs, have been recognized as regulators of immune cell-specific gene expression that mediate immune processes. These immune-related lncRNAs may play a vital role in immunotherapy resistance. Herein, we summarize current immune-related lncRNAs and their underlying roles in immune resistance to provide strategies for future research and therapeutic alternatives to overcome immunotherapy resistance.
Insights
Immune checkpoint inhibitors show promise for cancer treatment but face resistance. This review explores how immune-related long non-coding RNAs (lncRNAs) contribute to this resistance, offering insights for overcoming it.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- T-cell-based immunotherapies, including immune checkpoint inhibitors, are vital cancer treatments.
- A significant number of patients exhibit primary or secondary resistance to these therapies.
- Immune escape, driven by changes in cancer cells and the tumor microenvironment, is a key factor in resistance.
Purpose of the Study:
- To summarize current knowledge on immune-related long non-coding RNAs (lncRNAs).
- To elucidate the roles of these lncRNAs in mediating resistance to cancer immunotherapy.
- To propose future research directions and therapeutic strategies for overcoming immunotherapy resistance.
Main Methods:
- Literature review and synthesis of existing research on lncRNAs and immunotherapy resistance.
- Analysis of studies identifying immune-related lncRNAs and their functions.
- Identification of mechanisms by which lncRNAs influence immune responses and resistance.
Main Results:
- Immune-related lncRNAs are recognized regulators of immune cell gene expression and immune processes.
- These lncRNAs are implicated in the development of both primary and secondary resistance to immunotherapy.
- Alterations in cancer cells and the tumor microenvironment contribute to immune escape and resistance.
Conclusions:
- Immune-related lncRNAs represent a critical factor in immunotherapy resistance.
- Understanding these lncRNAs can reveal novel therapeutic targets.
- Targeting immune-related lncRNAs may offer new strategies to enhance immunotherapy efficacy and overcome resistance.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:39lncRNA - Long Non-coding RNAs
01:20Types of RNA
RNA Performs Diverse...
01:23Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
02:15Experimental RNAi
01:22MicroRNAs